

technologies; provide guidance and review on CDC's Tuberculosis Prevention Research portfolio and program priorities; and review the extent to which progress has been made toward eliminating tuberculosis.

ACET consists of 10 experts knowledgeable in the fields of public health, epidemiology, immunology, infectious diseases, pulmonary disease, pediatrics, tuberculosis, microbiology, or preventive health care delivery, who are selected by the Secretary of the United States Department of Health and Human Services.

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of the Council's objectives.

Nominees will be selected from experts having experience in tuberculosis prevention and control.

Experts in the disciplines of epidemiology, immunology, infectious diseases, pulmonary disease, pediatrics, tuberculosis, microbiology, preventive health care delivery, and experts in public health and other related disciplines will be considered. Members may be invited to serve up to four-year terms. The HHS policy stipulates that committee membership be balanced in terms of professional training and background, points of view represented and the council's function.

Consideration is given to a broad representation of geographic areas within the U.S., with equitable representation of the sexes, ethnic and racial minorities, and persons with disabilities. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government.

Candidates should submit the following items:

- Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address)
- A letter of recommendation from person(s) not employed by the U.S. Department of Health and Human Services
- A statement indicating the nominee's willingness to serve as a potential member of the Council.

Nominations should be submitted electronically or in writing, and must be postmarked by September 30, 2014, to: Margie Scott-Cseh, Committee Management Specialist, NCHHSTP, CDC, 1600 Clifton Road NE., Mailstop: E07, Atlanta, GA 30333, Email address: zkr7@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of

meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Gary J. Johnson,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014-00044 Filed 1-7-14; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension of Current Funding Opportunity Announcement and Grant Application Template for ACL Discretionary Grant Programs

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: The Administration for Community Living (ACL) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments on the collection of information by February 7, 2014.

ADDRESSES: Submit written comments on the collection of information by fax 202.395.6974 or by mail to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., Rm. 10235, Washington, DC 20503, Attn: Carolyn Lovett, Desk Officer for ACL.

FOR FURTHER INFORMATION CONTACT: Lori Stalbaum, (202) 357-3452 or lori.stalbam@acl.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, ACL has submitted the following proposed collection of information to OMB for review and clearance.

ACL is requesting an extension of the currently approved Administration on Aging (AoA) Funding Opportunity Announcement and Application Instructions Template for use for all ACL Discretionary Grant Programs, of which AoA is now a program center. This template provides the requirements and instructions for the submission of an application for discretionary grants funding opportunities. The template

may be found on the ACL Web site at www.acl.gov/Funding_Opportunities/Announcements/docs/ACL_PA_Template_FINAL_8-12-13.doc. ACL estimates the burden of this collection of information as follows:

Frequency: 15—20 Funding Opportunity Announcements published annually.

Respondents: State agencies, public agencies, private non-profit agencies, institutions of higher education, and organizations including tribal organizations.

Estimated Number of Responses: 350 annually.

Total Estimated Burden Hours: 16,800.

Dated: January 2, 2014.

Kathy Greenlee,

Administrator and Assistant Secretary for Aging.

[FR Doc. 2014-00059 Filed 1-7-14; 8:45 am]

BILLING CODE 4154-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]

Nonprescription Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Nonprescription Drugs Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the Agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 26, 2014, from 8 a.m. to 12:30 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/default.htm>; under the heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

Contact Person: Glendolynn S. Johnson, Center for Drug Evaluation and